Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials.

Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

Neurology. 2015 Aug 25;85(8):692-700. doi: 10.1212/WNL.0000000000001877. Epub 2015 Jul 24.

2.

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators.

N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839.

3.

Results of treatment of 22 navicular stress fractures and a new proposed radiographic classification system.

Saxena A, Fullem B, Hannaford D.

J Foot Ankle Surg. 2000 Mar-Apr;39(2):96-103.

PMID:
10789100
4.

Soft orthoses for athletes.

Hannaford DR.

J Am Podiatr Med Assoc. 1986 Oct;76(10):566-9. No abstract available.

PMID:
3772764
5.

Video analysis and treatment of overuse knee injury in cycling: a limited clinical study.

Hannaford DR, Moran GT, Hlavac HF.

Clin Podiatr Med Surg. 1986 Oct;3(4):671-8.

PMID:
2946395

Supplemental Content

Loading ...
Support Center